Back to AbbVie

AbbVie News

ABBV

AbbVie Adds Independent Director: John M. Carethers

AbbVie (ABBV) appointed Dr. John M. Carethers to its board on Oct 15, 2026, expanding to 13 members. Governance update for investors amid recent strategic activity.

ABBV

AbbVie Updates 2026 EPS Guidance (ABBV)

AbbVie (ABBV) revises 2026 EPS guidance to reflect Q3 IPR&D and milestone expenses tied to recent acquisitions and financing.

ABBV

AbbVie Completes Apogee Acquisition

AbbVie (ABBV) completes acquisition of Apogee Therapeutics, integrating assets into its pipeline. Transaction financed via senior notes and reflected in 2026 guidance.

ABBV

AbbVie Issues $9.75B Senior Notes for Apogee Deal

AbbVie (ABBV) raised $9.75B through senior notes to finance its Apogee acquisition, continuing a 2026 trend of debt-funded M&A and balance-sheet activity.

ABBV

AbbVie Updates Q2 and 2026 EPS Guidance

AbbVie revises Q2 and full-year 2026 EPS guidance to include IPR&D charges and milestone costs tied to acquisitions and contingent consideration.

ABBV

AbbVie Completes $7B Senior Notes Offering

AbbVie (ABBV) completed a $7B senior notes offering with maturities through 2066 on 2026-03-04, aligning with the company's ongoing debt-management strategy.

ABBV

ABBV $7.95B Senior Notes Issuance

AbbVie (ABBV) to issue $7.95B senior notes maturing 2028–2066. Read deal details, implications for debt profile, and investor considerations.

ABBV

AbbVie Finalizes Capstan and Gilgamesh Acquisitions

AbbVie (ABBV) completes acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals on 2025-10-31, expanding oncology and delivery tech pipeline.

ABBV

AbbVie Raises Quarterly Dividend to $1.73

AbbVie (ABBV) raises its quarterly dividend 5.5% to $1.73 on Oct. 31, 2025. Read implications for income investors and the firm's cash-return strategy.

ABBV

AbbVie Raises 2025 EPS Guidance After Q3 Results

AbbVie (ABBV) reported Q3 results and raised its 2025 adjusted EPS guidance. Read analysis on drivers, pipeline, risks and implications for shareholders.

ABBV

AbbVie (ABBV) Gains FDA Nod for Rinvoq Expansion

AbbVie (ABBV) wins FDA approval for an expanded Rinvoq indication, strengthening its immunology franchise as key oncology and neuroscience programs progress.

ABBV

AbbVie Cuts 2025 Adjusted EPS Guidance - ABBV

AbbVie (ABBV) lowers 2025 adjusted EPS guidance after a $2.7B IPR&D charge. Read the implications for the pipeline, shareholder returns and risks.

ABBV

AbbVie Settles Upadacitinib Patent Litigation

AbbVie (ABBV) settles patent litigation, delaying generic upadacitinib (Rinvoq) entry until April 2037. Key investor implications for immunology revenue and patent moat.